Intrexon Corporation Announces The Appointment of Peter Emtage, Ph.D., As Vice President, Synthetic Immunology

GERMANTOWN, Md.Dec. 4, 2014 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, today announced the appointment of Peter Emtage, Ph.D., as Vice President, Synthetic Immunology.  Dr. Emtage will focus on further advancing the Company's oncology and immunology platforms to bring the next generation of cellular-based solutions that overcome the limitations of current treatments and address the most challenging malignancies. 

"We are thrilled to have Peter join the executive team and look forward to his leadership within our expanding synthetic immunology group," said Krish S. Krishnan, Chief Operating Officer of Intrexon.  "Peter's expertise in guiding multi-functional teams to prioritize and advance immunotherapy projects from target identification to clinical application will be instrumental."

Dr. Emtage brings to Intrexon over sixteen years of biologics development experience in the fields of oncology, autoimmunity, infectious diseases, and inflammation. Most recently, Dr. Emtage was Vice President of Immune Mediated Therapy in the Oncology Innovative Medicines group at Medimmune, the biologics research and development subsidiary of AstraZeneca, where he was head of immunotherapy program development focused on oncology.  Dr. Emtage's responsibilities included the creation and implementation of a comprehensive immune therapy cancer strategy and coordination of this strategy with key partners across Medimmune and project teams. Prior to joining Medimmune, he held senior positions at Femta Pharmaceuticals and Nventa Biopharmaceuticals.  Dr. Emtage holds a B.S. and M.S. in Molecular Biology and Genetics from the University of Guelph, and received his Ph.D. in Molecular Virology, Immunology and Inflammation at McMaster University. His career started with a post-doctoral fellowship at the National Institutes of Health followed by his roles of Research Scientist at Aventis Pasteur and Instructor in Medicine at Harvard Medical School. He will report to Mr. Krishnan. 

"I am excited to be joining the expanding team of passionate and dedicated tumor immunologists at Intrexon to help assemble the next generation of CAR-T and other cell-based therapies," remarked Dr. Emtage. "From my evaluation of multiple technologies in the space, Intrexon's strategy and integrated suite of technologies are uniquely positioned for this rapidly evolving field of synthetic immunology over multiple horizons of growth."

About Intrexon Corporation
Intrexon Corporation (NYSE: XON) is a leader in synthetic biology focused on collaborating with companies in Health, Consumer, Food, Energy, and Environment Sectors to create biologically-based products that improve the quality of life and the health of the planet.  Through the company's proprietary UltraVector® platform and suite of technologies, Intrexon provides its partners with industrial-scale design and development of complex biological systems. The UltraVector® platform delivers unprecedented control over the quality, function, and performance of living cells. We call our synthetic biology approach and integrated technologies Better DNA®, and we invite you to discover more at www.DNA.com.

Trademarks
Intrexon, UltraVector, and Better DNA are trademarks of Intrexon and/or its affiliates.  Other names may be trademarks of their respective owners.

Safe Harbor Statement
Some of the statements made in this press release are forward-looking statements.  These forward-looking statements are based upon our current expectations and projections about future events and generally relate to our plans, objectives and expectations for the development of our business.  Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties and actual future results may be materially different from the plans, objectives and expectations expressed in this press release.

Suggested Articles

Orum Therapeutics raised $30 million to expand the applications for for its cell-penetrating antibody technology.

Genentech followed a $1 billion pact with Sosei Heptares with discovery deals around cancer and neurological diseases with Skyhawk and Convelo.

The partners will use wearable devices to assess how heart failure patients function and feel after being discharged from hospitals.